The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: Influenza virus is easily spread among the household contacts of an infected person, and prevention of influenza in household contacts can control spread of influenza in the community. OBJECTIVE: To investigate the efficacy of oseltamivir in preventing spread of influenza to household contacts of influenza-infected index cases (ICs). DESIGN AND SETTING: Randomized, double-blind, placebo-controlled study conducted at 76 centers in North America and Europe during the winter of 1998-1999. PARTICIPANTS: Three hundred seventy-seven ICs, 163 (43%) of whom had laboratory-confirmed influenza infection, and 955 household contacts (aged >/=12 years) of all ICs (415 contacts of influenza-positive ICs). INTERVENTIONS: Household contacts were randomly assigned by household cluster to take 75 mg of oseltamivir (n = 493) or placebo (n = 462) once daily for 7 days within 48 hours of symptom onset in the IC. The ICs did not receive antiviral treatment. MAIN OUTCOME MEASURE: Clinical influenza in contacts of influenza-positive ICs, confirmed in a laboratory by detection of virus shedding in nose and throat swabs or a 4-fold or greater increase in influenza-specific serum antibody titer between baseline and convalescent serum samples. RESULTS: In contacts of an influenza-positive IC, the overall protective efficacy of oseltamivir against clinical influenza was 89% for individuals (95% confidence interval [CI], 67%-97%; P<.001) and 84% for households (95% CI, 49%-95%; P<.001). In contacts of all ICs, oseltamivir also significantly reduced incidence of clinical influenza, with 89% protective efficacy (95% CI, 71%-96%; P<.001). Viral shedding was inhibited in contacts taking oseltamivir, with 84% protective efficacy (95% CI, 57%-95%; P<.001). All virus isolates from oseltamivir recipients retained sensitivity to the active metabolite. Oseltamivir was well tolerated; gastrointestinal tract effects were reported with similar frequency in oseltamivir (9.3%) and placebo (7.2%) recipients. CONCLUSION: In our sample, postexposure prophylaxis with oseltamivir, 75 mg once daily for 7 days, protected close contacts of influenza-infected persons against influenza illness, prevented outbreaks within households, and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963036t · Cited by 1,100
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
Influenza virus neuraminidase inhibitors
Gubareva, L. V., Kaiser, L., & Hayden, F. G. (2000) · The Lancet · doi:10.1016/s0140-6736(99)11433-8 · Cited by 730
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Self-citationHayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., & Straus, S. E. (1999) · JAMA · doi:10.1001/jama.282.13.1240 · Cited by 550
Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza
Hayden, F. G., Atmar, R. L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., & Mills, R. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411802 · Cited by 512
Evidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus
Gubareva, L. V., Matrosovich, M. N., Brenner, M. K., Bethell, R. C., & Webster, R. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/314440 · Cited by 432
Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families
Hayden, F. G., Belshe, R. B., Clover, R. D., Hay, A. J., Oakes, M. G., & Soo, W. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912213212502 · Cited by 416
Inhaled Zanamivir for the Prevention of Influenza in Families
Hayden, F. G., Gubareva, L. V., Monto, A. S., Klein, T. C., Elliott, M. J., Hammond, J. M., Sharp, S. J., & Ossi, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431801 · Cited by 371
ESTIMATING HOUSEHOLD AND COMMUNITY TRANSMISSION PARAMETERS FOR INFLUENZA
LONGINI, I. M., KOOPMAN, J. S., MONTO, A. S., & FOX, J. P. (1982) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113356 · Cited by 355
Hurwitz, E. S. (2000) · JAMA · doi:10.1001/jama.284.13.1677 · Cited by 313
Mendel, D. B., Tai, C. Y., Escarpe, P. A., Li, W., Sidwell, R. W., Huffman, J. H., Sweet, C., Jakeman, K. J., Merson, J., Lacy, S. A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.640 · Cited by 255
Emergence and Transmission of Influenza A Viruses Resistant to Amantadine and Rimantadine
Hayden, F. G., & Hay, A. J. (1992) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-77011-1_8 · Cited by 239
Some Aspects of the Design and Analysis of Cluster Randomization Trials
Donner, A. (1998) · Journal of the Royal Statistical Society Series C: Applied Statistics · doi:10.1111/1467-9876.00100 · Cited by 178
Sidwell, R. W., Huffman, J. H., Barnard, D. L., Bailey, K. W., Wong, M.-H., Morrison, A., Syndergaard, T., & Kim, C. U. (1998) · Antiviral Research · doi:10.1016/s0166-3542(97)00065-x · Cited by 170
Influenza. The Viruses and the Disease.
Tyrrell, D. A. J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-4-500_2 · Cited by 157
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine
Hayden, F. G., Sperber, S. J., Belshe, R. B., Clover, R. D., Hay, A. J., & Pyke, S. D. M. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.9.1741 · Cited by 148
Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults
Hayden, F. G., Gwaltney, J. M., de Castle, R. L. V., Adams, K. F., & Giordani, B. (1981) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.19.2.226 · Cited by 118
WILSON, L. A., & Brass, W. (1973) · Age and Ageing · doi:10.1093/ageing/2.2.92 · Cited by 98
Effectiveness of Rimantadine Prophylaxis of Children Within Families
Clover, R. D. (1986) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1986.02140210104036 · Cited by 70
Antiviral agents against respiratory viruses
Tremblay, C. L. (2001) · Clinical Microbiology Newsletter · doi:10.1016/s0196-4399(01)89050-4 · Cited by 2
Cited by
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Avian Influenza A (H5N1) Infection in Humans
(2005) · New England Journal of Medicine · doi:10.1056/nejmra052211 · Cited by 1,285
Containing Pandemic Influenza at the Source
Longini, I. M., Nizam, A., Xu, S., Ungchusak, K., Hanshaoworakul, W., Cummings, D. A. T., & Halloran, M. E. (2005) · Science · doi:10.1126/science.1115717 · Cited by 1,163
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
Metadata
- Authors
- Welliver, R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-02-14
- Volume
- 285
- Issue
- 6
- Pages
- 748
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2026309239
- Cited by
- 463
- References
- 21
- FWCI
- 22.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.